Immunovant, Inc. 8-K

What Happened

• Immunovant, Inc. announced its financial results for the fiscal third quarter and the nine months ended December 31, 2025 in a press release dated February 6, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K filed on February 6, 2026. The Form 8‑K was signed by Chief Financial Officer Tiago Girao.

Key Details

• Filing date: February 6, 2026 (Form 8‑K Items 2.02 and 9.01).
• Period covered: fiscal third quarter and nine months ended December 31, 2025.
• Exhibit(s) furnished: Exhibit 99.1 (press release dated Feb 6, 2026) and Exhibit 104 (Inline XBRL cover page data).
• The 8‑K furnishes the press release announcing the company’s quarterly results; the filing itself does not embed full financial statements beyond the press release exhibit.

Why It Matters

• This 8‑K signals an earnings update (quarterly results and nine‑month performance) that investors should review to assess Immunovant’s recent operating and financial trends. Retail investors should read the referenced press release (Exhibit 99.1) for the detailed numbers on revenue, earnings, cash position, or guidance that could affect the company’s share performance. The signature by the CFO indicates the filing is an official company disclosure.